WO2006114791A1 - Substituts du gras du lait humain - Google Patents

Substituts du gras du lait humain Download PDF

Info

Publication number
WO2006114791A1
WO2006114791A1 PCT/IL2006/000511 IL2006000511W WO2006114791A1 WO 2006114791 A1 WO2006114791 A1 WO 2006114791A1 IL 2006000511 W IL2006000511 W IL 2006000511W WO 2006114791 A1 WO2006114791 A1 WO 2006114791A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acids
fat
total
oil
composition
Prior art date
Application number
PCT/IL2006/000511
Other languages
English (en)
Inventor
Avidor Shulman
Gai Ben Dror
Hala Laouz
Dov Yaakobi
Zohar Bar-On
Gregory Blinder
Iris Meiri-Bendek
Yael Herzog
Original Assignee
Enzymotec Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymotec Ltd. filed Critical Enzymotec Ltd.
Priority to KR1020137031555A priority Critical patent/KR20130136013A/ko
Priority to KR1020077027507A priority patent/KR101368603B1/ko
Priority to EP06728308A priority patent/EP1876913A1/fr
Priority to CN2006800216508A priority patent/CN101198261B/zh
Priority to US11/912,946 priority patent/US9332771B2/en
Priority to JP2008508414A priority patent/JP2008538915A/ja
Priority to BRPI0609904-1A priority patent/BRPI0609904A2/pt
Publication of WO2006114791A1 publication Critical patent/WO2006114791A1/fr
Priority to IL186927A priority patent/IL186927A/en
Priority to HK08112260.0A priority patent/HK1117350A1/xx
Priority to US15/149,278 priority patent/US10004247B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/08—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with fatty acids
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/10—Ester interchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to human milk fat substitutes, processes for their preparation, uses thereof and fat blend and infants formulae containing them.
  • Lipids in general are the building blocks of life. They are used as building blocks of membranes, cells and tissues, as energy sources, either immediate or stored, as precursors to a variety of other bio- molecules, as well as biochemical signals. In all biochemical processes lipids have an important role.
  • lipids and especially triglycerides, are consumed in the human nutrition on a daily basis. In most cases, these lipids are metabolized and used for energy storage, precursors for biosynthesis of other lipids or bio-molecules. Whatever the fate of the lipids in the metabolic pathways, during and after their consumption, they interact with other nutrients or their metabolic products.
  • Palmitic acid (Cl6:0) is the predominant saturated fatty acid (SAFA), constituting 20-25% of the fatty acids in mature human milk. 70-75% of this fatty acid are esterified at the sn-2 position of the triglycerides.
  • SAFA saturated fatty acid
  • palmitic acid present in vegetable oils which are most commonly used in the manufacture of infant formulas, is esterified at the sn-1 and sn-3 positions, while the sn-2 position is predominantly occupied by unsaturated fatty acids.
  • Linoleic (18:2) and linolenic (C18:3) acids cannot be synthesized in animal tissues and must be obtained from the diet, i.e. ultimately from plants. There is an absolute requirement for these so called “essential fatty acids" for growth, reproduction and good health.
  • triglycerides in human mother milk 5-20% of the total C 18:3 and 20-23% of the total C18:2 are esterified at the sn-2 position of the glycerol backbone [Lopez-Lopez A. (2002) European Journal of Clinical Nutrition; 56:1242-54, Innis S.M. (1994) Lipids; 29:541-5].
  • the triglyceride digestive process of the neonate is complex. It is initiated by a gastric phase catalyzed by gastric or lingual lipase [Hamosh M. (1990) Nutrition; 6:421-8]. This initial lipolysis allows maximal activity of pancreatic colipase- dependent lipase during the intestinal phase of digestion. The pancreatic lipase system attacks the triglyceride with a high degree of positional ' specificity. Lipolysis occurs predominantly at the sn-1 and sn-3 positions, yielding two free fatty acids and a 2-monoglyceride [Mattson F.H. & Beck L.H. (1956) J. Biol.
  • Monoglycerides are well absorbed independent of their constituent fatty acid. In contrast, the absorption of free fatty acids varies greatly, depending on their chemical structure. Mono and polyunsaturated fatty acids are well absorbed, as are saturated fatty acids of 12 carbons or less in chain length. The coefficient of absorption of free long chain saturated fatty acids i.e. palmitic acid is relatively low [Jensen C. et al. (1988) Am. J. Clin.
  • Palmitic acid when absorbed from milk px formula with rearranged triglycerides as a s ⁇ -2 monoglyceride, is conserved through the process of triglyceride reassembly in the enterocyte and secretion in plasma lipoprotein triglycerides [Innis S.M. et al. (1995) J. Nutr.; 125:73-81]. It has also been shown that the distribution of saturated fatty acids in human milk and infant formula is a determinant of the fatty acid distribution of infant plasma triglycerides and phospholipids [Innis S.M. et al. (1994) Lipids.; 29:541-545].
  • Fecal excretion of calcium was closely related to the fecal excretion of fat. This study also showed that urinary phosphorus excretion increased and phosphorus retention decreased when infants were fed the formula containing high levels of palmitic acid at the sn-1,3 positions. These findings presumably reflect lower availability of calcium for deposition in bones.
  • EP 0 209 327 describes a substitute milk fat composition which is suitable for use as replacement fat in infant formulations.
  • the claimed fat composition at least 43.5% of the total saturated fatty acids residues are bound to the sn-2 position of the triglycerides. Additionally, at least 50% of the fatty acids occupying the sn-2 position are saturated.
  • the fat composition of this patent is produced from an oil or fat characterized by high levels of saturated fatty acids, specifically palmitic acid.
  • EP 0 495 456 also discloses substitute human milk fat compositions.
  • the claimed compositions have at least 40% of the total saturated fatty acids located at the sn- 2 position of the triglycerides contained in the composition. These fat composition are also characterized by comprising 0.2-7% of linolenic acid moieties (C18:3, ⁇ - 3), 70% of which are bonded at the sn-1 and 3-positions of the glycerol moieties.
  • the fat composition of EP 0 495 456 is also produced by transesterifications of a triglyceride source rich in saturated fatty acids, specifically palmitic acid. This source, such as top fraction of palm oil, can contain palmitic acid at levels higher than 80% and even 90%.
  • US Patent No. 5,658,768 discloses a multiple-step process for preparing triglyceride compositions in which more than 40% of the saturated fatty acid moieties are at the sn-2 position. Many of the steps involve enzymatic )modifications.
  • Applicant's WO2004/036987 describes a fat composition which can be used to create human milk fat substitutes which have great similarity to human milk fat and/or can be used at relatively low levels to yield such human milk fat substitutes.
  • This composition is also produced starting from triglycerides sources rich in palmitic acid.
  • the inventors of the current invention have addressed the issue of cost by producing a unique fat composition, described in said WO2004/036987, offering HMF substitutes with still high levels of similarity to HMF, by using relatively low levels of the synthetic fat-base composition of that invention in the total fat blend used in the infant formula.
  • HMF substitutes that offer a relatively high degree of the total saturated fatty acids located at the sn-2 position, yielding fat compositions with more than 40% of their total saturated fatty acids positioned at the sn-2 position (but less than 50%).
  • Such HMF substitutes were produced by high degree of dilution of fat-base compositions, such as described by EP 0 209 327 or EP 0 495 456, with simple and cost-effective vegetable oils. These blends, however, have a lower ratio of sn-2 palmitic to total palmitic (-40-43%) than can be found in HMF (-70%). Nevertheless, clinical studies [Lien et al.
  • these HMF substitutes characterized in having at least 40% of their saturated fatty acids located at the sn-2 position, are obtained by diluting fat-bases with high levels of sn-2 palmitic acid, as well as a high ratio of sn-2 palmitic to total palmitic acid, with a variety of vegetable triglycerides to obtain a blend in which at least 40% of the saturated fatty acids are bound at the sn-2 position. This ratio is usually between 40 to 45%.
  • the fat bases used in the preparation of these HMF substitutes are produced by interesterifying triglycerides rich in palmitic acid with an excess of a mixture of free fatty acids, rich in oleic acid.
  • the present invention relates to an enzymatically prepared fat base composition
  • a mixture of vegetable- derived triglycerides characterized in that less than 50% of the fatty acid residues bonded at the sn-2 position are saturated; and/or the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is less than about 43.5% of jbhe total amount of saturated fatty acid residues; wherein said fatty acid residues are C12, C12, C16 or C16 acids, optionally other fatty acids, and any mixture thereof comprising at least two acids.
  • substantially all of the saturated fatty acids bonded at the sn-2 position of the glycerol backbone are palmitic acid residues.
  • at least 60%, preferably at least 75%, more preferably at least 85% of the saturated fatty acids at the sn-2 position of the glycerol backbone are palmitic acid residues.
  • the fat base composition of the invention at least 40%, preferably 45-65%, of the unsaturated fatty acid moieties at the sn-1 and sn-S positions are oleic acid moieties. Particularly, at least 45%, preferably 54- 65%, of the unsaturated fatty acid moieties at the sn-1 and sn-3 positions are oleic acid moieties. Alternatively, at least 35%, preferably 40-52%, of said unsaturated fatty acid moieties at the sn-1 and sn-S positions are oleic acid moieties.
  • the unsaturated fatty acid moieties at the sn-1 and sn-3 positions may be linoleic acid moieties.
  • at least 9%, preferably 10-20%, of the unsaturated fatty acid moieties at the sn-1 and sn-3 positions are linoleic acid moieties.
  • at least 4%, preferably 5-10%, of the unsaturated fatty acid moieties at the sn-1 and sn-S positions are linoleic acid moieties.
  • the fat base composition of the invention from about 0.2 to about 15%, preferably from about 7% to about 14%, more preferably from about 11% to about 12.5% of the total fatty acid moieties at the s ⁇ -1 and sn-3 positions are lauric acid moieties.
  • the invention relates to a substitute human milk fat composition
  • a substitute human milk fat composition comprising a blend of at least 25% or at least 30% of the fat base ⁇ composition of the invention with up to 75%, or ' .respectively up to 70%, of at least one vegetable oil.
  • the vegetable oil may be selected from the group comprising soy oil, palm tree oil, canola oil, coconut oil, palm kernel oil, sunflower oil, corn oil and rapeseed oil, but is not limited thereto. These oils may be randomized before mixing with the fat base composition, as detailed below.
  • substitute human milk fat composition of the invention from about 33% to about 45%, preferably about 36% to about 43%, even more preferably about 40% of the total palmitic acid residues are bonded at the sn-2 position of the glycerol backbone.
  • the invention relates to an infant formula comprising the fat base composition or substitute human milk fat composition of the .
  • infant formula comprising at least one protein component and at least one fat component, wherein said fat component is the fat base composition or substitute human milk fat composition of the invention, the formula optionally also comprising vitamins, minerals, nucleotides, amino acids and carbohydrates, and any other nutritionally beneficiary constituents.
  • the invention relates to a first process for the preparation of the fat base composition of the invention, as defined above, the process comprising the steps of:
  • the triglyceride mixture is randomized prior to the reaction in order to enrich the sn-2 position with saturated fatty acids (by increasing the share of saturated fatty acids bonded at the sn-2 position). Randomization may be performed chemically, by using basic or acidic catalyst, or enzymatically, by using a non-selective lipase.
  • This first process of the invention may optionally further comprise a step of fractionation preceding the deodorization step (e).
  • the triglyceride mixture used in this process of the invention may preferably contain from 48-57% saturated fatty acids, preferably palmitic acid.
  • the free fatty acids source used in this process of the invention may preferably comprise about 2-5% C16:O, 60-80% C18:1 and 1-4% Cl8:0 fatty acids.
  • the invention relates to a process for the preparation of the substitute human milk fat composition of the invention, as defined above, this process comprising admixing a fat base composition of the invention with at least one vegetable oil, preferably at a ratio of from about 0.4:1 to about 4:1, to give a blend wherein the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is from about 33% to about 43.5, preferably about 43% more preferably about 40% of the total amount of saturated fatty acid residues.
  • the fat base composition of the invention is admixed with the vegetable oil at a ratio of from about 2.3:1 to about 1:1, resulting in a blend wherein the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is from about 33% to about 40% of the total amount of saturated fatty acid residues. .
  • the admixed vegetable oils used for preparing a substitute human milk fat are optionally randomized to have 33% of the palmitic acid residues esterified at the sn-2 position.
  • the randomization enables to significantly decrease the amount of fat base needed for preparing a substitute milk fat composition for infant formulae which possesses the desired ratio of saturated fatty acid residues bonded at the sn-2 position out of the total amount of saturated fatty acid residues. This embodiment is of major financial importance.
  • the randomization of the admixed vegetable oils may be performed chemically using basic or acidic catalyst, or enzymatically using a non-selective lipase.
  • the invention relates to a second process for the preparation of the fat base composition of the invention, as defined above, the process comprising the steps of:
  • the triglycerides mixture is optionally randomized prior to the reaction in order to enrich the saturated fatty acid moieties at the sn-2 position of the glycerol backbone.
  • the randomization may be performed by a standard interesterification process, either chemically by using acidic or basic catalyst (e.g. sodium methoxide) or enzymatically by using a non-selective lipase.
  • the said free unsaturated fatty acids source preferably contains from about 10% to about 25% saturated fatty acids of 14 carbons atoms or less, preferably lauric acid.
  • the second process of the invention may also optionally further comprise a step of fractionation preceding the deodorization step (e).
  • the triglyceride mixture may contain at least 75% of palmitic acid.
  • the free fatty acids source may contain about 5-25% C12:0, 0.05-2 %C14:0, 1-5% C16:0, 55-75% C18:l and 1-5 % C18:O fatty acids of total fatty acids.
  • the invention relates to a process for the preparation of the substitute human milk fat composition of the invention, as defined above, this process comprising admixing a fat base composition of the invention with at least one vegetable oil, preferably at a ratio of from about 0.4:1 to about 4:1, to give a blend wherein the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is from about 33% to about 43.5, preferably about 43%, more preferably about 40% of the total amount of saturated fatty acid residues.
  • the fat base composition of the invention is admixed with the vegetable oil at a ratio of from about 2.3:1 to about 1:1, resulting in a blend wherein the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is from about 33% to about 40% of the total amount of saturated fatty acid residues.
  • the admixed vegetable oils are optionally randomized so as to have about 33% of the total palmitic acid residues esterified at the sn-2 position.
  • the randomization enables to significantly reduce the amount of fat base needed to obtain the desired ratio of saturated fatty acid Residues bonded at the sn-2 position out of the total amount of saturated fatty acid residues in the resulting substitute HMF preparation.
  • the randomization of the admixed vegetable oils may be performed chemically using basic or acidic catalyst, or enzymatically using a non-selective lipase.
  • the invention relates to a process for the preparation of a HMP mimetic composition, comprising the steps of:
  • % said free fatty acid to said glyceride mixture being from about 5:1 to about
  • step (e) optionally deodorizing the product of step (d).
  • the obtained product has 0-20% C12:O fatty acids out of the total fatty acids, preferably 10-15%; 0-15% C14:O fatty acids out of the total fatty acids, preferably 5-10%; 8-30% C16:O fatty acids out of the total fatty acids, preferably 20-25%; 1-6% C18:0 fatty acids out of the total fatty acids, preferably 3-5%; 20- 50% C18:l fatty acids out of the total fatty acids, preferably 30-40%; 5-30% C18:2 fatty acids out of the total fatty acids, preferably 10-20%; 0.2-4% C18:3 fatty acids out of the total fatty acids, preferably 1.5-3%; other fatty acids are present in levels of less than 10% of the total fatty acids, preferably less than 5%.
  • a major advantage of this product is that it is suitable, without any further blending, for use as an ingredient to infant formulas.
  • the source triglyceride mixture is randomized, either chemically or enzymatically, prior to the reaction in order to enrich the saturated fatty acids jmoieties at the sn-2 position.
  • the invention also relates to a fat composition which is similar to and can serve as a substitute for HMF obtainable by the process of the invention.
  • HMF substitute composition may preferably be characterized by a fatty acid profile suitable for infant nutrition, preferably mimicking the fatty acid profile of HMF, most preferably minimizing loss of calcium through fatty acid soap formation, wherein said composition has an sn-2 saturated to total saturated fatty acids of at least 33%, preferably at least 40%, more preferably above 45%, even more preferably above 50%, most preferably above 59%.
  • This composition has a sn-2 palmitic to total palmitic ratio of at least 40%, preferably above 43%, more preferably above 45%.
  • the invention relates to the use of a fat base composition of the invention, or prepared by any of the processes of the invention, in the preparation of a substitute human milk fat composition for infant formulas.
  • the invention relates to a process for the preparation of a substitute HMF composition.
  • This process comprises admixing a suitable fat base composition with at least one vegetable oil, wherein the vegetable oil is randomized prior to being mixed with the fat base composition.
  • a suitable fat base is a mixture of structured lipids, produced by reacting glycerides with free fatty acids, in the presence of a stereospecific selective lipase.
  • This fat base has 0-20% C12:O fatty acids out of the total fatty acids, preferably 10-15%; 0-15% C14:O fatty acids out of the total fatty acids, preferably 5-10%; 20-55% C16:0 fatty acids out of the total fatty acids, of which above 38% are esterified at the sn-2 position; 1-7% Cl8:0 fatty acids out of the total fatty acids, preferably 3- 5%; 25-65% C18:l fatty acids out of the total fatty acids, preferably 30-40%; 2- 40% C18:2 fatty acids out of the total fatty acids, preferably 10-20%; 0-8% C18:3 fatty acids out of the total fatty acids, preferably 1.5-3%; other fatty acids are present in levels of less than 8% of the total fatty acids, preferably less than 5%.
  • the vegetable oil may be selected from the group consisting of soy oil, palm tree oil, canola oil, coconut oil, palm kernel oil, sunflower oil, corn oil and rapeseed oil, but is not limited thereto.
  • the admixed vegetable oils used for preparing a substitute human milk fat are randomized.
  • the randomization yields an oil having 33% of its palmitic acid residues esterified at the sn-2 position of the glycerol backbone.
  • the randomization enables to significantly decrease the amount of fat base needed for preparing a substitute milk fat composition for infant formulas which possesses the desired ratio of saturated fatty acid residues bonded at the sn-2 position out of the total amount of saturated fatty acid residues.
  • This embodiment is of major financial importance.
  • the randomization of the admixed vegetable oils may be performed chemically using basic or acidic catalyst, or enzymatically using a non-selective lipase.
  • Randomized blending oils may contribute to ⁇ -linolenic acid (C18:3) and linoleic acid (C18:2) distribution with higher similarity to HMF, in comparison with the natural oil contribution.
  • the fat base composition and oil/s are mixed at a suitable ratio, which may be determined by the desired profile of the resulting blend.
  • the fat base composition and the blending oil/s may be mixed at a ratio of from about 0.13:1 to about 4:1, to give a blend wherein the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is from about 33% to about 43.5, preferably about 43%, more preferably about 40% of the total amount of saturated fatty acid residues.
  • the amount of saturated fatty acid residues bonded at the sn-2 position of the glycerol backbone is above 43.5%.
  • the ratio of the ingredients can thus be changed to give a blend with a desired or predetermined fatty acid profile.
  • the invention relates to a. process for the preparation of a f fat base composition suitable for use as an ingredient of infant formula, comprising the steps of (a) reacting a randomized triglyceride mixture which has a suitable profile of fatty acids which has a palmitic acid content of more than about 35% out of the total fatty acids, with a suitable free unsaturated fatty acids source which source has a palmitic acid content of less than 10% out of the total free fatty acids, in the presence of an insoluble catalyst, the ratio of said free fatty acids to said glyceride mixture being from about 7:1 to about 1:1.
  • step (b) removing the catalyst; (c) distilling the excess free fatty acids; optionally (d) bleaching the oil; and optionally (e) deodorizing the product of step (d).
  • the randomization of the triglyceride mixture may be performed chemically using basic or acidic catalyst, or enzymatically using a non-selective lipase.
  • novel fat-base compositions that are characterized by having less than 50% of their sn-2 fatty acids as saturated.
  • novel HMF substitutes can be produced by interesterification of relatively low-palmitic acid triglycerides.
  • the fat-base compositions can be used for preparing fat blends (final, ready for use as infants formulas components) which are characterized by a total saturated (specifically palmitic acid) fatty acids level similar to HMF and a ratio of sn-2 saturated (substantially palmitic) fatty acids to total saturated (palmitic) fatty acids higher than 33% and preferably lower than 43.5%, more preferably lower than 40%.
  • This fat-base composition, the process for its preparation and its various uses constitute the first aspect of the present invention.
  • the present invention relates to the production of a fat concentrate by interesterification process, in 'which the starting material is not as rich in palmitic acid, as described in the prior art, but a combination of vegetable oils as the triglyceride raw material, having a palmitic acid content of about 50% and total saturated fatty acids content lower than 60%.
  • the compositions of two exemplary triglyceride starting materials are shown in Table 1.
  • These raw materials can be used as starting material in an interesterification process, employing suitable specific 1,3-lipases, to produce a fat-base composition, which in turn can be used to produce HMF substitutes (replacers), such as those described above.
  • HMF substitutes replacements
  • These substitutes provide limited similarity to HMF by having a ratio of sn-2 palmitic acid to total palmitic acid higher than 33%, thus improving the infant's absorption of calcium and of fatty acids, used as an energy source.
  • HMF substitutes of the present invention exhibit improved calcium absorption over simple blends of vegetable oils used in infant formulas, have a maximal sn-2 palmitic acid to total palmitic acid ratio of preferably 1:3 (33%), and are produced at lower cost compared to HMF substitutes produced from prior art fat-bases, such as those having a ratio of sn-2 palmitic acid to total palmitic of over 50%.
  • the low-palmitic raw material triglycerides described above may be randomized before the interesterification (as described below) and further reacted with a free fatty acids mixture containing relatively high quantities of oleic acid, at ratios of £1.5:1 (FFA to triglycerides) as in Example 1, or even as low as 1:1, as in Example 2. It may be noted that prior art compositions usually have ratios of 5:1 or as low as 3:1 (FFA to fat).
  • FAC fatty acid composition of the fat bases produced from the triglycerides of Examples 1 and 2 is described in Table 2.
  • FAC fatty acid composition
  • SAFA Saturated Fatty Acids
  • FFA free fatty acid
  • the resulting fat-base has a sn-2 saturated fatty acid (SAFA) content of less than 50% and the ratio of sn-2 palmitic to total palmitic is also below 50%.
  • SAFA saturated fatty acid
  • fat bases can be further blended with vegetable oils to produce a final HMF substitute/replacer, with a sn-2 saturated FA to total saturated FA ratio higher than 33% (39.3% when using fat base of Example 2) and sn-2 palmitic to total palmitic ratio of about 44 % (44.2% when using fat base of Example 2).
  • Tables 3 and 4 describe the blending of the fat base of Example 2, with the vegetable oils detailed therein and composition of the blend.
  • the total palmitic acid content is 22%, comparable to the level found in HMF.
  • a process and triglyceride compositions employed therein wherein the triglycerides are blends of palm stearin interesterified with palm oil, palm stearin interesterified with rapeseed oil, and the like.
  • the typical fatty acid composition of the resulting triglycerides starting material is less than 60%, preferably between about 48 to about 57% saturated fatty acids out of total fatty acids.
  • the maximal ratio between SAFA at the sn-2 position to total SAFA is about 1:3 (33%).
  • the free fatty acids (FFA) used are a source rich in oleic acid and low in saturated fatty acids.
  • Typical values are 2-5% C16:O, 60-80% C18:l, 1-4% C18:0.
  • Possible sources are rapeseed fatty acids, palm kernel oil C18 fraction fatty acids, high oleic sunflower oil FFA and others. Also a combination between at least two different sources of fatty acids is possible.
  • the ratio between triglycerides (TAG) and FFA is typically from about 40:60 (TAG:FFA) to about 50:50.
  • the fatty acid used for enriching sn positions 1 and 3 with unsaturated fatty acids can come from free fatty acids, as exemplified here, but also from alkyl esters of fatty acids, preferably methyl or ethyl esters, as well as glyceride esters.
  • the current invention relates to a fat composition that is produced by interesterification of a triglycerides source with a relatively low amount of free fatty acids.
  • the free fatty acid source is rich in both oleic acid and lauric acid. It is known from the prior art that fat bases can be produced by using a large excess of unsaturated fatty acids during the interesterification. Excesses of up to 5 parts FFA to fat were used.
  • the invention relates to a process for preparing fat-base concentrates characterized in using small or equi-weight amounts of oleic acid rich fatty acids mixtures, which are also relatively rich in lauric acid (above 3%).
  • the triglycerides are rich in palmitic acid, preferably over 70%, and contain very small amounts of linolenic acid.
  • the palmitic-rich triglycerides may be randomized by a standard chemical or enzymatic interesterification process as described below.
  • the palmitic-rich triglycerides are reacted with fatty acids mixtures which have relatively high levels of lauric acid, thus reducing the sn-2 SAFA to total SAFA ratio, whilst maintaining a high sn-2 palmitic to total palmitic ratio and not adversely affecting calcium and fatty acid intake by the infant (see above), as compared with similar blends obtained from fat bases with high sn-2 palmitic to total palmitic ratios.
  • the ratio between the fatty acids and triglycerides in the interesterification process is from 1.5:1 (Example; 3, Table 5) to 2:1 (Example 4, Table 6).
  • the resulting fat bases have sn-2 SAFA to total SAFA ratio of less than 43.5, while the sn-2 palmitic to total palmitic ratio is about 50%.
  • the triglycerides are typically low Iodine Value (IV) palm stearin with up to 80% palmitic acid.
  • the triglycerides can be a blend of interesterified palm stearin with palm oil, palm stearin with rapeseed oil, palm oil, etc.
  • the ratio between sn-2 SAFA to total SAFA of the triglycerides is maximum 33%.
  • the free fatty acids are a source rich in oleic acid, low in saturated long chain fatty acids of C14 and up, and enriched with lauric acid. Typical values are 2-5% C16:0, 60-80% C18:l, 1-4% C18:0, 5-30% C12 out of the total fatty acids.
  • Possible sources are rapeseed fatty acids, palm kernel oil C 18 fraction fatty acids, lauric oils (such as palm kernel oil and coconut oil),, high oleic sunflower oil free fatty acids and others. Also a combination between two or more different sources of fatty acids is possible.
  • Table 7 below exemplifies the preparation of a blend, based on the fat-base of Example 4, with additional vegetable oils as detailed in the Table. The admixed vegetable oils of the example were randomized prior to their blending with the fat base as described below.
  • the fatty acid composition of the resulting blend can be seen in Table 8.
  • the sn-2 SAFA to total SAFA of the blend is 37% while the sn-2 palmitic to total palmitic s 44%.
  • this blend is comparable in sn-2 palmitic to total palmitic ratio, total palmitic content and the consequent contribution to calcium intake to similar blends obtained from fat bases of significantly higher sn-2 palmitic to total palmitic ratios.
  • the present invention relates to an interesterification fat product that can be used as the fat fraction of infant formula, without prior blending with additional vegetable or other oils, and that is characterized by a total saturated (specifically palmitic acid) fatty acids level similar to HMF and a ratio of sn-2 saturated (palmitic) fatty acids to total saturated (palmitic) fatty acids higher than 33%, containing all the necessary fatty acids required in infants nutrition.
  • the invention relates to the direct production of a HMF substitute, with a fatty acid composition and sn-2 palmitic to total palmitic ratio, and sn-2 SAFA to total SAFA ratios, similar to that of the blends described above, without the necessity to first obtain a suitable fat base, to be then blended with the other ingredients.
  • the product of the interesterification can be used as a final HMF replacer for infant formulas in terms of its fatty acid composition and ratios improved over simple blends of vegetable oils, resulting in improved calcium and fatty acid intake.
  • triglyceride mixture which may be randomized prior to the reaction, as described herein
  • a fatty acid mixture characterized by its high level of oleic acid and total fatty acid profile designed to substantially mimic the sn-1,3 fatty acid profile of HMF.
  • the triglycerides can be of high palmitic acid levels or of lower palmitic acid levels (as described above), according to the target grade and level of similarity to HMF of the desired HMF substitute.
  • the fatty acids mixture used in the interesterification can include fatty acids from C8 to C24, including saturated such as lauric, myristic, stearic, mono-di- unsaturated, such as oleic, palmitoleic, and linoleic, and polyunsaturated, such as linolenic, arachidonic, docosahexaenoic, etc.
  • the desired fatty acid mixture is obtained by mixing vegetable oils and fats as shown in Table 9, which serves as an example for raw triglycerides source.
  • the composition of the derived free fatty acids is the same as the composition of the raw triglycerides.
  • the ratio between the fatty acids mixtures and triglycerides in the interesterification reaction can be 5:1 to 1:2, preferably 3:1 to 1:1 and the reaction can be carried out by a continuous bed process or a fixed bed process using jbiocatalysts, preferably immobilized, preferably of 1,3 lipase activity.
  • the resulting HMF substitutes can be of sn-2 palmitic to total palmitic ratios of above 33%, preferably over 40%, and up to 80%.
  • Table 10 exemplifies a HMF substitute that was produced using free fatty acid mixture of Example 5 (Table 9) and randomized palm olein at a ratio of 1.2:1.
  • the sn-2 SAFA to total SAFA of the HMF substitute is 34.5% while the sn-2 palmitic to total palmitic is 45.3%.
  • this composition is comparable in sn-2 palmitic to total palmitic, total palmitic content and the consequent contribution to calcium intake to similar blends obtained from fat bases.
  • the invention relates to the randomization of the resulting fat base triglycerides starting material and to the randomization of the admixed oils prior their blending with the fat base. Both these aspects of the invention have major advantages, exemplified and discussed in more detail below. It may be mentioned that while being a known process per se, neither randomization of triglycerides starting material for the production of nutritional products, particularly for infants, babies, toddlers and children, nor randomization of blending oils used in the preparation of infant formulas, have been described. This is one of the unique developments shown in the present application.
  • the resulting triglycerides which serve as starting material for preparation of the fat base composition are preferably randomized by a standard interesterification process, either chemically by using acidic or basic catalyst (e.g. sodium methoxide), or enzymatically by using a non-selective lipase.
  • acidic or basic catalyst e.g. sodium methoxide
  • non-selective lipase e.g. sodium methoxide
  • standard palm oil contains about 40% C 16 out of the total fatty ⁇ acids, and only 5-20% C 16 out of the total C 16 are esterified at the sn-2 position. Following random interesterification of the palm oil, 33% C 16 out of the total C 16 are bonded at the sn-2 position.
  • palm stearin IV 15 with 79% C16 content out of the total fatty acids, of which only 27.4% are esterified at the sn-2 position.
  • the product shows 79% C 16 content out of total fatty acids, with 33% C16 out of the total C16 esterified at the sn-2 position.
  • Table 11 compares a fat base produced using randomized palm stearin with a fat base produced using non-randomized palm stearin. Randomized and non-randomized palm stearin IVl 5 were reacted separately with commercial oleic free fatty acids at a ratio of 1:4 of palm stearin to free fatty acids. After the reaction ended, the catalyst was separated, the free fatty acids were removed using steam distillation and the triglyceride fraction was analyzed. Table 11 demonstrates that using non-randomized palm stearin, results in a fat base with 29.8% C16 fatty acids out of the total fatty acids, of which only 63.1% are esterified at the sn-2 position.
  • the invention relates to a process for preparing fat base compositions in which the raw triglycerides source is randomized either chemically or enzymatically.
  • the admixed vegetable oils used for blending are preferably randomized, either chemically or enzymatically, prior to their blending with the fat base composition.
  • the randomization process randomly distributes the fatty acids of oil or fat between the three src-positions on the glycerol backbone.
  • the low sn-2 palmitic to total palmitic ratio of vegetable oils is elevated to 33%.
  • the randomization process is carried out routinely on many oils and fats in the industry, mainly in order to change their physical properties for a specific application (e.g. changing the melting point of a fat).
  • the randomization is carried out for improvement of the sn-2 saturated to total saturated ratio of the admixed oils, thereby reducing to a minimum any negative effect of the admixed oils on the sn-2 saturated to total saturated ratio of the blend.
  • Table 13 shows that in order to obtain 21% C 16 where 42% of them are esterified to the sn-2 position only 47% of the same fat base are required jwhen the blending oils are randomized. This significant difference in the required amount of fat base emphasizes the importance of using randomized blending oils for cost saving purposes.
  • the randomization of blending oils is beneficial also for blends made from fat bases other than the fat bases described in the present invention.
  • the fat bases described in EP 0 209 327 or EP 0 495 456 or by applicant in said WO2004/036987 may be blended with randomized vegetable oils rather than with natural vegetable oils.
  • This aspect of the invention enables achieving the same percentage of C16 and the same ratio of sn-2 palmitic acid residue to total palmitic acid residues as described by the above mentioned applications, while using less fat base and thus saving in the blend production costs.
  • Table 14 shows that in order to achieve EP 0 209 327 blend 2 composition (26% C16 52.6% of which being esterified to the sn-2 position), 50% of the fat base of Sample 1 of EP 0 209 327 are needed, using the non-randomized blending oils used in said patent. As may be seen from Table 15, by using the randomized blending oils of the present invention only 43% of the fat base of Sample 1 of EP 0 209 327 are needed for achieving 26% C 16 of which 52.6% are esterified to the sn-2 position. This significant difference in the required amount of fat base (14% saving) demonstrates the importance and advantage of using randomized blending oils for cost saving purposes also for blends made from fat bases other jthan the fat bases described in and subject of the present invention.
  • Table 16 shows that by using randomized blending oils it is possible to improve the percentage of sn-2 palmitic acid residues out of total palmitic acid residues in blends such as described in EP 0 209 327 (Blends 1-4).
  • Randomized blending oils may contribute to ⁇ -linolenic acid (C18:3) and linoleic acid (C18:2) distribution with higher similarity to HMF, in comparison with the natural oil contribution.
  • Rapeseed oil and soybean oil are the main sources for vegetal linolenic acid and are commonly used in the manufacture of infant formulas.
  • Table 17 shows the differences between HMF, natural and randomized rapeseed and soybean oils in the sn-2 distribution of linoleic and linolenic acids.
  • rapeseed oil 45-61% of the linolenic acid residues, and 32-47% of the linoleic acid residues are esterified at the sn-2 position.
  • the distribution of linolenic acid and linoleic acid in rapeseed oil differs largely from that of HMF.
  • soybean oil In soybean oil, the distribution of linolenic acid (27-29% of the ⁇ -linolenic acid are bonded at the sn-2 position) resembles that of randomized soybean oil (33%). However, in natural soybean oil, 40-43% of the linoleic acid are esterified at the sn-2 position, while in randomized soybean oil only 33% of the linoleic acid are esterified at the sn-2 position. In HMF only 20-23% of the linoleic acid residues are bonded at the sn-2 position. Thus, the utilization of randomized soybean oil instead of natural soybean oil improves the resemblance of linoleic acid distribution to that of HMF, while maintaining a similar ⁇ -linolenic acid distribution.
  • the randomization of the admixed vegetable oils may be performed by a standard interesterification process, either chemically by using acidic or basic catalyst (e.g. sodium methoxide) or enzymatically by using a non-selective lipase.
  • acidic or basic catalyst e.g. sodium methoxide
  • HMF substitutes of the different aspects of the invention can be used as the fat fractions of infant formula and as fat fraction of baby foods, toddlers' foods, children and young people foods, as well as adult nutrition.
  • fat and lipid are used herein interchangeably.
  • Lipids under the scope of this invention, include triglycerides and derivatives, such as mono- and di-glycerides.
  • infant formula encompasses infant formulas (for newborn to 6 months old infants), follow-up formulas (for 6-12 months old babies) and growing-up formulas (for 1-3 years old children).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pediatric Medicine (AREA)
  • Dairy Products (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne des substituts du gras du lait humain (HMF), des procédés de préparation de ceux-ci, des utilisations de ceux-ci et des mélanges de gras et des formules pour nourrissons refermant ceux-ci. Une composition basique de gras selon l'invention comprend un mélange de triglycérides dérivés de légumes, moins de 50 % des résidus des acides gras liés au niveau de la position sn-2 étant saturés; et/ou la quantité des résidus des acides gras saturés liés au niveau de la position sn-2 du squelette du glycérol étant inférieure à environ 43,5 % de la quantité totale des résidus des acides gras saturés. En général, sensiblement tous les acides gras saturés liés au niveau de la position sn-2 du squelette du glycérol sont des résidus d'acides palmitiques. L'invention concerne également des compositions de substitution du HMF comprenant un mélange d'au moins 25 % ou d'au moins 30 % de la composition basique de gras selon l'invention avec jusqu'à 75 % ou respectivement jusqu'à 70 % d'au moins une huile végétale. L'invention concerne enfin des procédés de préparation des compositions basiques de gras et un mélange de gras, ainsi que des formules pour nourrissons comprenant la composition basique de gras ou la composition de substitution du gras du lait humain.
PCT/IL2006/000511 2005-04-27 2006-04-27 Substituts du gras du lait humain WO2006114791A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020137031555A KR20130136013A (ko) 2005-04-27 2006-04-27 모유 지방 대체물
KR1020077027507A KR101368603B1 (ko) 2005-04-27 2006-04-27 모유 지방 대체물
EP06728308A EP1876913A1 (fr) 2005-04-27 2006-04-27 Substituts du gras du lait humain
CN2006800216508A CN101198261B (zh) 2005-04-27 2006-04-27 人乳脂替代品
US11/912,946 US9332771B2 (en) 2005-04-27 2006-04-27 Human milk fat substitutes
JP2008508414A JP2008538915A (ja) 2005-04-27 2006-04-27 ヒト乳脂代用物
BRPI0609904-1A BRPI0609904A2 (pt) 2005-04-27 2006-04-27 substitutos da gordura do leite humano
IL186927A IL186927A (en) 2005-04-27 2007-10-25 Fatty preparations prepared in enzymatic processes, breast milk substitutes and infant formulas containing them, and processes for their preparation
HK08112260.0A HK1117350A1 (en) 2005-04-27 2008-11-07 Human milk fat substitutes
US15/149,278 US10004247B2 (en) 2005-04-27 2016-05-09 Process for the preparation of human milk fat substitutes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL168263 2005-04-27
IL16826305 2005-04-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/912,946 A-371-Of-International US9332771B2 (en) 2005-04-27 2006-04-27 Human milk fat substitutes
US15/149,278 Continuation US10004247B2 (en) 2005-04-27 2016-05-09 Process for the preparation of human milk fat substitutes

Publications (1)

Publication Number Publication Date
WO2006114791A1 true WO2006114791A1 (fr) 2006-11-02

Family

ID=36636497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/000511 WO2006114791A1 (fr) 2005-04-27 2006-04-27 Substituts du gras du lait humain

Country Status (10)

Country Link
US (2) US9332771B2 (fr)
EP (1) EP1876913A1 (fr)
JP (1) JP2008538915A (fr)
KR (2) KR101368603B1 (fr)
CN (1) CN101198261B (fr)
BR (1) BRPI0609904A2 (fr)
HK (1) HK1117350A1 (fr)
IL (1) IL186927A (fr)
RU (1) RU2413430C2 (fr)
WO (1) WO2006114791A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104381A1 (fr) * 2007-02-28 2008-09-04 Loders Croklaan B.V. Procédé de production d'une composition de glycéride
WO2008132713A1 (fr) * 2007-04-29 2008-11-06 Shemen Industries Ltd. Composition d'huile nourrissante pour nourrissons et jeunes enfants
DE102007022694A1 (de) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
WO2009012982A3 (fr) * 2007-07-25 2009-03-19 Loders Croklaan Bv Procédé
WO2009047754A2 (fr) * 2007-10-09 2009-04-16 Enzymotec Ltd. Compositions lipidiques pour traiter des troubles gastro-intestinaux et favoriser les développement et maturation intestinaux
WO2009062663A3 (fr) * 2007-11-14 2009-11-12 Lipid Nutrition B.V. Composition
EP2143340A1 (fr) * 2008-07-07 2010-01-13 Nestec S.A. Composition nutritionnelle comprenant des acides aminés libres et des lipides structurés
EP2330916A2 (fr) * 2008-08-25 2011-06-15 Brandeis University Huile alimentaire contenant du myristate sn-2
WO2011071367A1 (fr) * 2009-12-11 2011-06-16 N.V. Nutricia Effets d'empreinte métabolique de lipides structurés
WO2011135564A1 (fr) * 2010-04-26 2011-11-03 Enzymotec Ltd. Procédés et compositions lipidiques pour favoriser le développement de la flore intestinale
US8153407B2 (en) 2005-09-08 2012-04-10 Loders Croklaan B.V. Process for producing a triglyceride
WO2013068879A2 (fr) 2011-11-10 2013-05-16 Pfizer Inc. Formule pour nourrisson riche en palmitate sn-2 et en oligofructose
CN104099240A (zh) * 2014-07-11 2014-10-15 嘉必优生物工程（武汉）有限公司 制造结构油脂的设备
US8877812B2 (en) 2010-12-29 2014-11-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
WO2016097221A1 (fr) * 2014-12-19 2016-06-23 Nestec S.A. Nutrition de nourrisson avec une protéine hydrolysée et de l'acide palmitique
WO2016097220A1 (fr) * 2014-12-19 2016-06-23 Nestec S.A. Nutrition de nourrisson avec des protéines hydrolysées, du calcium ionique et de l'acide palmitique
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
EP2956010B1 (fr) 2013-02-12 2017-01-04 Loders Croklaan B.V. Composition de matières grasses
CN106359663A (zh) * 2016-08-24 2017-02-01 深圳精益油脂技术有限公司 采用罗非鱼的油脂制备的母乳脂肪替代物、应用及方法
CN112195199A (zh) * 2020-10-29 2021-01-08 赞宇科技集团股份有限公司 一种1，3-二油酸-2-棕榈酸甘油三酯的生产方法
WO2022008718A1 (fr) 2020-07-10 2022-01-13 Bunge Loders Croklaan B.V. Composition de matière grasse
US11399559B2 (en) 2015-07-29 2022-08-02 Abbott Laboratories Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
CN102225060A (zh) 2005-12-19 2011-10-26 雅培制药有限公司 β-羟基-β-甲基丁酸盐在调节1-型和2-型细胞因子生成失衡中的应用
US8498729B2 (en) * 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
WO2010068086A1 (fr) * 2008-12-11 2010-06-17 N.V. Nutricia Composition nutritionnelle à globules de lipides de grande taille
MX2012006048A (es) * 2009-11-25 2012-09-07 Nestec Sa Aceites estables en oxidación y mezclas y composiciones que los contienen.
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
PE20121729A1 (es) 2010-01-29 2013-01-16 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2443933A1 (fr) * 2010-10-19 2012-04-25 Nestec S.A. Composition de colorant à café
WO2012173467A1 (fr) * 2011-06-16 2012-12-20 N.V. Nutricia Effets d'empreinte métabolique de composant lipidique conçu de manière spécifique
CN102827885B (zh) * 2011-06-17 2016-04-20 丰益(上海)生物技术研发中心有限公司 含有1,3-二不饱和脂肪酰-2-饱和脂肪酰甘油酯的组合物及其制备方法与用途
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8906441B2 (en) 2011-09-22 2014-12-09 Hormel Foods Corporation Peanut spread
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN102757988B (zh) * 2012-07-25 2015-01-21 浙江大学 一种1,3-二油酸-2-棕榈酸甘油三酯的制备方法
WO2014166789A1 (fr) * 2013-04-10 2014-10-16 Nestec S.A. Lait infantile à faible teneur en acides gras à chaîne moyenne dans des proportions spécifiques et son utilisation pour favoriser et/ou assurer une croissance équilibrée chez les nourrissons
US20160166527A1 (en) * 2013-08-01 2016-06-16 Loders Croklaan B.V. Glyceride Composition
US20160227810A1 (en) * 2013-10-17 2016-08-11 University Of Georgia Research Foundation, Inc. Structured triacylglycerols and methods for making the same
CN103689101B (zh) * 2013-12-17 2015-08-12 江苏科技大学 蚕蛹油来源的合成母乳脂肪替代品的制备方法
CN103725721B (zh) * 2013-12-20 2015-06-10 润科生物工程（福建）有限公司 一种富含二十二碳六烯酸的结构油脂及其制备方法
WO2016004825A1 (fr) * 2014-07-07 2016-01-14 嘉必优生物工程（武汉）有限公司 Composition comprenant un glycéride d'acide 2-palmitique et son procédé de préparation, une graisse structurale comprenant l'acide 2-palmitique acide gras 1,3-bi-insaturé et procédé de préparation, et aliments spéciaux
US20160015068A1 (en) * 2014-07-16 2016-01-21 Mead Johnson Nutrition Company Nutritional formulas containing oil blends and uses thereof
CN106108023B (zh) * 2015-05-05 2020-01-14 嘉必优生物技术（武汉）股份有限公司 特殊膳食
CN105028659B (zh) * 2015-05-14 2018-10-30 江南大学 一种人乳替代脂组合物
CN106916631A (zh) * 2015-12-28 2017-07-04 丰益(上海)生物技术研发中心有限公司 油脂组合物、母乳脂肪替代物及其制备方法
CN106912622B (zh) * 2015-12-28 2020-10-30 丰益(上海)生物技术研发中心有限公司 一种母乳脂肪替代物及其制造方法
WO2017153998A1 (fr) * 2016-03-10 2017-09-14 Enzymotec Ltd. Compositions lipidiques et leurs utilisations
CN109475141A (zh) * 2016-08-17 2019-03-15 酶学技术有限公司 油掺合物和其制备方法
JP6904009B2 (ja) * 2017-03-31 2021-07-14 日油株式会社 油脂の製造方法
CN107549313B (zh) * 2017-10-12 2020-09-22 中国农业科学院农产品加工研究所 基于甘油三酯分析模拟母乳脂肪的婴儿奶粉油脂配制方法
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
KR102559886B1 (ko) * 2018-03-15 2023-07-27 주식회사 삼양사 모유 지방 대체지를 함유하는 유지 조성물 및 이를 포함하는 화장료 조성물
JP2019162055A (ja) * 2018-03-19 2019-09-26 株式会社明治 エネルギー代謝促進用組成物
CN108309129B (zh) * 2018-03-28 2020-07-17 贝亲母婴用品（常州）有限公司 一种纤柔巾及其制备方法
JP7359539B2 (ja) * 2018-03-29 2023-10-11 日清オイリオグループ株式会社 油脂組成物、加熱調理用油脂組成物、加熱調理用油脂組成物の製造方法、並びに、油脂組成物における酸価上昇及び色調上昇の抑制方法
CN108642097B (zh) * 2018-07-04 2021-07-09 嘉必优生物技术（武汉）股份有限公司 一种三饱和脂肪酸甘油酯的制备方法
TW202100019A (zh) * 2019-03-01 2021-01-01 荷蘭商弗里斯蘭康必奶荷蘭有限公司 脂肪組成物及基於其之營養組成物
CN113575697B (zh) * 2021-07-30 2022-10-18 江南大学 一种基于动物乳脂肪的母乳脂肪替代品的制备方法
CN113615743B (zh) * 2021-07-30 2022-04-15 江南大学 一种模拟母乳脂肪结构的人乳替代脂的制备方法
CN113832200B (zh) * 2021-07-30 2023-12-01 江南大学 一种母乳化结构脂的制备方法
WO2023244719A1 (fr) * 2022-06-16 2023-12-21 Savor Foods Limited Formulations de graisse

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0209327A2 (fr) 1985-07-12 1987-01-21 Unilever Plc Composition de graisse
EP0376628A2 (fr) 1988-12-29 1990-07-04 American Home Products Corporation Composition de graisse pour aliments pour bébé
EP0495456A1 (fr) 1991-01-16 1992-07-22 Daikin Industries, Limited Composition de caoutchouc fluoré
EP0496456A1 (fr) 1991-01-23 1992-07-29 Unilever N.V. Substituts de graisse de lait maternel
WO1995031110A1 (fr) 1994-05-13 1995-11-23 American Home Products Corporation Compositions de matiere grasse corandomisees pour formules destinees a des nourrissons
US5508048A (en) 1989-11-09 1996-04-16 Van Den Bergh Foods Co. Enzymatic transesterification starting from high erucic cruciferae oils
US5658768A (en) 1993-05-13 1997-08-19 Loders Croklaan B.V. Process for production of human milk fat replacers by enzymatic conversion of triglycerides
US5972412A (en) 1993-09-14 1999-10-26 Van Den Bergh Foods Company, Division Of Conopco, Inc. Natural triglyceride fats
US6297279B1 (en) 1997-07-22 2001-10-02 Nestac S.A. Lipid composition for infant formula and method of preparation
WO2004036987A1 (fr) 2002-10-25 2004-05-06 Tormod Drengstig Dispositif de conchyliculture
WO2005036987A1 (fr) * 2003-10-22 2005-04-28 Enzymotec Ltd. Mimetique de lipide du lait maternel humain utilise comme complement alimentaire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
IL100072A (en) * 1990-11-30 1995-03-30 American Home Prod Cordomized fat preparations, especially for use in baby food
JP3120906B2 (ja) * 1992-08-25 2000-12-25 雪印乳業株式会社 β−パルミチン酸含有トリグリセリドの製造方法
DE69405096T2 (de) 1993-05-13 1998-01-22 Loders Croklaan Bv Muttermilch-ersatzstoffe aus umgeestertentriglyceridmischungen
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides
WO1997028695A1 (fr) * 1996-02-09 1997-08-14 Unilever N.V. Composition comestible a base de graisse vegetale
DE69718455T2 (de) 1997-07-22 2003-04-30 Societe Des Produits Nestle S.A., Vevey Lipidzusammensetzung für Säuglingsnährpräparat und Herstellungsverfahren
EP1062873A1 (fr) * 1999-12-13 2000-12-27 N.V. Nutricia Aliment amélioré pour bébés, hydrolysat de protéines utilisables dans un tel aliment pour bébés, et procédé de préparation de cet hydrolysat
AU2003251557A1 (en) * 2002-06-28 2004-01-19 Richard C. Theuer Fat compositions for infant formula and methods therefor
JP2005065645A (ja) * 2003-08-27 2005-03-17 J-Oil Mills Inc 食用油脂組成物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0209327A2 (fr) 1985-07-12 1987-01-21 Unilever Plc Composition de graisse
US4876107A (en) 1985-07-12 1989-10-24 Unilever Patent Holdings Bv Substitute milk fat compositions
EP0376628A2 (fr) 1988-12-29 1990-07-04 American Home Products Corporation Composition de graisse pour aliments pour bébé
US5508048A (en) 1989-11-09 1996-04-16 Van Den Bergh Foods Co. Enzymatic transesterification starting from high erucic cruciferae oils
EP0495456A1 (fr) 1991-01-16 1992-07-22 Daikin Industries, Limited Composition de caoutchouc fluoré
EP0496456A1 (fr) 1991-01-23 1992-07-29 Unilever N.V. Substituts de graisse de lait maternel
US5658768A (en) 1993-05-13 1997-08-19 Loders Croklaan B.V. Process for production of human milk fat replacers by enzymatic conversion of triglycerides
US5972412A (en) 1993-09-14 1999-10-26 Van Den Bergh Foods Company, Division Of Conopco, Inc. Natural triglyceride fats
WO1995031110A1 (fr) 1994-05-13 1995-11-23 American Home Products Corporation Compositions de matiere grasse corandomisees pour formules destinees a des nourrissons
US6297279B1 (en) 1997-07-22 2001-10-02 Nestac S.A. Lipid composition for infant formula and method of preparation
WO2004036987A1 (fr) 2002-10-25 2004-05-06 Tormod Drengstig Dispositif de conchyliculture
WO2005036987A1 (fr) * 2003-10-22 2005-04-28 Enzymotec Ltd. Mimetique de lipide du lait maternel humain utilise comme complement alimentaire

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
CARLSON S.E. ET AL., AM. J. CLIN. NUTR., vol. 44, 1986, pages 798 - 804
CARNIELLI V.P. ET AL., J. PEDIATR. GASTROENTEROL. NUTR., vol. 23, 1996, pages 553 - 560
CARNIELLI V.P., AM. J. CLIN. NUTR., vol. 61, 1995, pages 1037 - 1042
CARNIELLI, J. PEDIATR. GASTR. AND NUTR., 1995
CARNIELLI, J. PEDIATR. GASTR. AND NUTR., 1996
CHAPPEL J.E. ET AL., J. PEDIATR., vol. 108, 1986, pages 439 - 447
FILER L.J. ET AL., J. NUTR., vol. 99, 1969, pages 293 - 8
FILER, AM. J. CLIN. NUTR., 1969
FINLEY; DAVIDSON, PEDIATRICS, vol. 65, no. 1, 1980, pages 132 - 8
HAMOSH M., NUTRITION, vol. 6, 1990, pages 421 - 8
HANNA F.M. ET AL., PEDIATR., vol. 45, 1970, pages 216 - 224
HANNA, J. PEDIATR. GASTROENTEROL. NUTR., 1970
HERNELL O. ET AL.: "Perinatal Nutrition.", 1988, ACADEMIC PRESS, pages: 259 - 272
INNIS S.M. ET AL., AM. COLL. NUTR., vol. 11, 1992, pages 63S - 8S
INNIS S.M. ET AL., AM. J. CLIN. NUTR., vol. 5, 1990, pages 994 - 1000
INNIS S.M. ET AL., J. NUTR., vol. 125, 1995, pages 73 - 81
INNIS S.M. ET AL., LIPIDS, vol. 29, 1994, pages 541 - 545
INNIS S.M., AM. J. CLIN. NUTR., vol. 57, 1993, pages 382 - 390
INNIS S.M., LIPIDS, vol. 29, 1994, pages 541 - 5
INNIS, ACTA. PEADIATR. SCAND., 1993
JENSEN C., AM. J. CLIN. NUTR., vol. 43, 1988, pages 745 - 51
KOLETZKO B. ET AL., EUR. J. PEDIATR., vol. 148, 1989, pages 669 - 75
LIEN E.L., J. PED. GASTR. NUTR., vol. 52, no. 2, 1997, pages 167 - 174
LIEN ET AL., J PEDIATR GASTROENTEROL NUTR., vol. 25, no. 2, 1997, pages 167 - 74
LIEN ET AL., JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1997, pages 167 - 74
LIEN, J. PEDIATR., vol. 125, no. 5, 1994, pages 62 - 8
LÓPEZ-LÓPEZ A., EARLY HUM. DEV., vol. 65, 2001, pages S83 - S94
LOPEZ-LOPEZ A., EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol. 56, 2002, pages 1242 - 54
LUCAS A. ET AL., ARCH. DIS. CHILD., vol. 77, 1997, pages F178 - F187
LUCAS, J. PEDIATR. GASTR. AND NUTR., 1997
MATTSON F.H.; BECK L.H., J. BIOL. CHEM., vol. 219, 1956, pages 735 - 740
NELSON S.E. ET AL., J. AMER. COLL. NUTR., vol. 17, 1998, pages 327 - 332
NELSON SE ET AL., AM. J. CLIN. NUTR., vol. 64, 1996, pages 291 - 296
NELSON, J. PEDIATR. GASTR. AND NUTR., 1996
OSTROM K.M. ET AL., J. AM. COLL. NUTR., vol. 21, no. 6, 2002, pages 564 - 569
OSTROM, J. PEDIATR. GASTROENTEROL. NUTR., 2002
PUTNAM J.C. ET AL., AM. J. CLIN. NUTR., vol. 36, 1982, pages 106 - 114
QUINLAN PT ET AL., J. PEDIATR. GASTR. AND NUTR., vol. 20, 1995, pages 81 - 90
See also references of EP1876913A1
SMALL D.M., ANNU. REV. NUTR., vol. 11, 1991, pages 413 - 434
SMALL, J. AM. COLL. NUTR., 1991
SMALL, J. NUTR., 1991
TANTIBHEDHYANGKUL; HASHIM, PEDIATRICS, vol. 61, no. 4, 1978, pages 537 - 45
TOMMARELLI R.M., J. NUTR., vol. 95, 1968, pages 583 - 90
VAN BIERVLIET J.P ET AL., ACTA. PAEDIATR. SCAND., vol. 70, 1981, pages 851 - 6
WANG C.S. ET AL., J. BIOL. CHEM., vol. 258, 1983, pages 9197 - 9202
WIDDOWSON E.M., BR. MED. J., vol. 1, 1975, pages 633 - 5

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44719E1 (en) 2005-09-08 2014-01-21 Loders Croklaan B.V. Process for producing a triglyceride
US8153407B2 (en) 2005-09-08 2012-04-10 Loders Croklaan B.V. Process for producing a triglyceride
WO2008104381A1 (fr) * 2007-02-28 2008-09-04 Loders Croklaan B.V. Procédé de production d'une composition de glycéride
CN101679909B (zh) * 2007-02-28 2013-01-16 荷兰洛德斯克罗科兰有限公司 甘油酯组合物的制备方法
US9695384B2 (en) 2007-02-28 2017-07-04 Loders Croklaan B.V. Process for producing a glyceride composition
US20170267945A1 (en) * 2007-02-28 2017-09-21 Loders Croklaan B.V. Process for Producing a Glyceride Composition
EP2115107B1 (fr) 2007-02-28 2018-04-11 Loders Croklaan B.V. Procédé de production d'une composition de glycéride
WO2008132713A1 (fr) * 2007-04-29 2008-11-06 Shemen Industries Ltd. Composition d'huile nourrissante pour nourrissons et jeunes enfants
DE102007022694A1 (de) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
EP2173197B1 (fr) 2007-07-25 2019-07-03 Bunge Loders Croklaan B.V. Procédé
WO2009012982A3 (fr) * 2007-07-25 2009-03-19 Loders Croklaan Bv Procédé
US8980949B2 (en) 2007-10-09 2015-03-17 Enzymotec Ltd. Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
US9107439B2 (en) 2007-10-09 2015-08-18 Enzymotec Ltd. Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
KR101354547B1 (ko) 2007-10-09 2014-01-22 엔지모테크 리미티드 위장 장애의 치료 및 장 발달 및 성숙의 촉진용의 지질 조성물
WO2009047754A3 (fr) * 2007-10-09 2009-05-22 Enzymotec Ltd Compositions lipidiques pour traiter des troubles gastro-intestinaux et favoriser les développement et maturation intestinaux
RU2469545C2 (ru) * 2007-10-09 2012-12-20 Энзимотек Лтд. Липидная композиция для лечения желудочно-кишечных нарушений и активации развития и созревания кишечника
WO2009047754A2 (fr) * 2007-10-09 2009-04-16 Enzymotec Ltd. Compositions lipidiques pour traiter des troubles gastro-intestinaux et favoriser les développement et maturation intestinaux
AU2008309140B2 (en) * 2007-10-09 2013-05-09 Frutarom Limited Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
US9561207B2 (en) 2007-10-09 2017-02-07 Enzymotec Ltd. Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
AU2008309140B9 (en) * 2007-10-09 2013-07-04 Frutarom Limited Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
EP2219476B1 (fr) 2007-11-14 2016-04-20 Loders Croklaan B.V. Composition d'alimentation infantile
WO2009062663A3 (fr) * 2007-11-14 2009-11-12 Lipid Nutrition B.V. Composition
EP2143340A1 (fr) * 2008-07-07 2010-01-13 Nestec S.A. Composition nutritionnelle comprenant des acides aminés libres et des lipides structurés
EP3560351A1 (fr) * 2008-07-07 2019-10-30 Société des Produits Nestlé S.A. Composition nutritionnelle comprenant des acides aminés libres et des lipides structurés
WO2010003790A1 (fr) * 2008-07-07 2010-01-14 Nestec S.A. Composition nutritive comportant des acides aminés libres et des lipides structurés
EP2330916A4 (fr) * 2008-08-25 2011-11-23 Univ Brandeis Huile alimentaire contenant du myristate sn-2
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
EP2330916A2 (fr) * 2008-08-25 2011-06-15 Brandeis University Huile alimentaire contenant du myristate sn-2
CN102724976B (zh) * 2009-12-11 2014-10-22 N·V·努特里奇亚 构造的脂质的代谢印记作用
US9044446B2 (en) 2009-12-11 2015-06-02 N.V. Nutricia Metabolic imprinting effects of structured lipids
CN102724976A (zh) * 2009-12-11 2012-10-10 N·V·努特里奇亚 构造的脂质的代谢印记作用
WO2011071367A1 (fr) * 2009-12-11 2011-06-16 N.V. Nutricia Effets d'empreinte métabolique de lipides structurés
WO2011071371A1 (fr) * 2009-12-11 2011-06-16 N.V. Nutricia Effets d'empreinte métabolique de lipides structurés
EP2338484A1 (fr) * 2009-12-11 2011-06-29 N.V. Nutricia Effets metaboliques des lipides structures
US9433599B2 (en) 2010-04-26 2016-09-06 Enzymotec Ltd. Methods and lipid compositions for promoting development of gut flora
WO2011135564A1 (fr) * 2010-04-26 2011-11-03 Enzymotec Ltd. Procédés et compositions lipidiques pour favoriser le développement de la flore intestinale
US8877812B2 (en) 2010-12-29 2014-11-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
US9446005B2 (en) 2010-12-29 2016-09-20 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
US9433586B2 (en) 2010-12-29 2016-09-06 Abbott Laboratories Methods of improving tolerance related to feeding in an infant, toddler, or child
US9844517B2 (en) 2010-12-29 2017-12-19 Abbott Laboratories Nutritional products including a novel fat system including fatty acids
US9078846B2 (en) 2010-12-29 2015-07-14 Abbott Laboratories Nutritional products including monoglycerides and fatty acids
US9078847B2 (en) 2010-12-29 2015-07-14 Abbott Laboratories Nutritional products including a novel fat system including monoglycerides
WO2013068879A2 (fr) 2011-11-10 2013-05-16 Pfizer Inc. Formule pour nourrisson riche en palmitate sn-2 et en oligofructose
EP2956010B1 (fr) 2013-02-12 2017-01-04 Loders Croklaan B.V. Composition de matières grasses
CN104099240A (zh) * 2014-07-11 2014-10-15 嘉必优生物工程（武汉）有限公司 制造结构油脂的设备
WO2016097220A1 (fr) * 2014-12-19 2016-06-23 Nestec S.A. Nutrition de nourrisson avec des protéines hydrolysées, du calcium ionique et de l'acide palmitique
RU2703177C2 (ru) * 2014-12-19 2019-10-15 Сосьете Де Продюи Нестле С.А. Питание для младенцев с гидролизованным белком, ионным кальцием и пальмитиновой кислотой
RU2703172C2 (ru) * 2014-12-19 2019-10-15 Сосьете Де Продюи Нестле С.А. Питание для младенцев с гидролизованным белком и пальмитиновой кислотой
WO2016097221A1 (fr) * 2014-12-19 2016-06-23 Nestec S.A. Nutrition de nourrisson avec une protéine hydrolysée et de l'acide palmitique
US11877587B2 (en) 2014-12-19 2024-01-23 Societe Des Produits Nestle S.A. Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid
US11399559B2 (en) 2015-07-29 2022-08-02 Abbott Laboratories Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form
CN106359663A (zh) * 2016-08-24 2017-02-01 深圳精益油脂技术有限公司 采用罗非鱼的油脂制备的母乳脂肪替代物、应用及方法
WO2022008718A1 (fr) 2020-07-10 2022-01-13 Bunge Loders Croklaan B.V. Composition de matière grasse
CN112195199A (zh) * 2020-10-29 2021-01-08 赞宇科技集团股份有限公司 一种1，3-二油酸-2-棕榈酸甘油三酯的生产方法

Also Published As

Publication number Publication date
US20160249665A1 (en) 2016-09-01
KR20080009732A (ko) 2008-01-29
US10004247B2 (en) 2018-06-26
EP1876913A1 (fr) 2008-01-16
CN101198261B (zh) 2013-05-15
CN101198261A (zh) 2008-06-11
KR20130136013A (ko) 2013-12-11
US20080193624A1 (en) 2008-08-14
JP2008538915A (ja) 2008-11-13
HK1117350A1 (en) 2009-01-16
IL186927A0 (en) 2008-02-09
US9332771B2 (en) 2016-05-10
RU2007143995A (ru) 2009-06-10
IL186927A (en) 2013-10-31
BRPI0609904A2 (pt) 2010-05-11
KR101368603B1 (ko) 2014-02-27
RU2413430C2 (ru) 2011-03-10

Similar Documents

Publication Publication Date Title
US10004247B2 (en) Process for the preparation of human milk fat substitutes
US9282748B2 (en) Human breast milk lipid mimetic as a dietary supplement
US9695384B2 (en) Process for producing a glyceride composition
JP3021499B2 (ja) 乳児処方用ランダム化パーム油脂組成物
US8206772B2 (en) Structured lipid compositions and methods of formulation thereof
EP1928989B1 (fr) Procédé de production de triglycérides
US8153407B2 (en) Process for producing a triglyceride
CN102113574B (zh) 一种婴幼儿食品用油脂组合物的制备方法
KR20010079767A (ko) 감량된 칼로리의 가소성 지방 조성물
WO2015050220A1 (fr) Composition d'huile/graisse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 186927

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008508414

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006728308

Country of ref document: EP

Ref document number: 8978/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077027507

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007143995

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680021650.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006728308

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11912946

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0609904

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020137031555

Country of ref document: KR